Carbon ion radiotherapy for unresectable localized axial soft tissue sarcoma

and the Working Group for Carbon Ion Radiotherapy for Bone and Soft Tissue Sarcomas

Research output: Contribution to journalArticle

3 Citations (Scopus)

Abstract

Carbon ion radiotherapy is known for its high-precision dose distribution and high biological effectiveness. We evaluated the results of carbon ion radiotherapy in 128 patients with unresectable localized axial soft tissue sarcoma at a single institution. The patients’ median age was 54 years, and the median follow-up period was 49.4 (range 6.4-146.4) months. The median tumor volume was 356 cm3. The 5-year local control, overall survival, and disease-free survival rates were 65%, 46%, and 39%, respectively. In the univariate analysis, tumor volume, local control, and incidences of metastases were significantly related to overall survival. In the multivariate analysis, tumor volume and local control were significantly related to overall survival. We did not find any factors related to local control. Five patients required surgical intervention because of adverse events in the bones. Carbon ion radiotherapy may be a treatment option for unresectable axial soft tissue sarcoma.

Original languageEnglish
Pages (from-to)4308-4314
Number of pages7
JournalCancer Medicine
Volume7
Issue number9
DOIs
Publication statusPublished - Sep 1 2018

Fingerprint

Heavy Ion Radiotherapy
Tumor Burden
Sarcoma
Survival
Disease-Free Survival
Multivariate Analysis
Survival Rate
Neoplasm Metastasis
Bone and Bones
Incidence
Therapeutics

Keywords

  • carbon ion radiotherapy
  • charged particle therapy
  • radiotherapy
  • soft tissue sarcoma

ASJC Scopus subject areas

  • Oncology
  • Radiology Nuclear Medicine and imaging
  • Cancer Research

Cite this

and the Working Group for Carbon Ion Radiotherapy for Bone and Soft Tissue Sarcomas (2018). Carbon ion radiotherapy for unresectable localized axial soft tissue sarcoma. Cancer Medicine, 7(9), 4308-4314. https://doi.org/10.1002/cam4.1679

Carbon ion radiotherapy for unresectable localized axial soft tissue sarcoma. / and the Working Group for Carbon Ion Radiotherapy for Bone and Soft Tissue Sarcomas.

In: Cancer Medicine, Vol. 7, No. 9, 01.09.2018, p. 4308-4314.

Research output: Contribution to journalArticle

and the Working Group for Carbon Ion Radiotherapy for Bone and Soft Tissue Sarcomas 2018, 'Carbon ion radiotherapy for unresectable localized axial soft tissue sarcoma', Cancer Medicine, vol. 7, no. 9, pp. 4308-4314. https://doi.org/10.1002/cam4.1679
and the Working Group for Carbon Ion Radiotherapy for Bone and Soft Tissue Sarcomas. Carbon ion radiotherapy for unresectable localized axial soft tissue sarcoma. Cancer Medicine. 2018 Sep 1;7(9):4308-4314. https://doi.org/10.1002/cam4.1679
and the Working Group for Carbon Ion Radiotherapy for Bone and Soft Tissue Sarcomas. / Carbon ion radiotherapy for unresectable localized axial soft tissue sarcoma. In: Cancer Medicine. 2018 ; Vol. 7, No. 9. pp. 4308-4314.
@article{f70384074c0c4dc499bdf74c872e980e,
title = "Carbon ion radiotherapy for unresectable localized axial soft tissue sarcoma",
abstract = "Carbon ion radiotherapy is known for its high-precision dose distribution and high biological effectiveness. We evaluated the results of carbon ion radiotherapy in 128 patients with unresectable localized axial soft tissue sarcoma at a single institution. The patients’ median age was 54 years, and the median follow-up period was 49.4 (range 6.4-146.4) months. The median tumor volume was 356 cm3. The 5-year local control, overall survival, and disease-free survival rates were 65{\%}, 46{\%}, and 39{\%}, respectively. In the univariate analysis, tumor volume, local control, and incidences of metastases were significantly related to overall survival. In the multivariate analysis, tumor volume and local control were significantly related to overall survival. We did not find any factors related to local control. Five patients required surgical intervention because of adverse events in the bones. Carbon ion radiotherapy may be a treatment option for unresectable axial soft tissue sarcoma.",
keywords = "carbon ion radiotherapy, charged particle therapy, radiotherapy, soft tissue sarcoma",
author = "{and the Working Group for Carbon Ion Radiotherapy for Bone and Soft Tissue Sarcomas} and Reiko Imai and Tadashi Kamada and Nobuhito Araki and Satoshi Abe and Yukihide Iwamoto and Toshihumi Ozaki and Hirokazu Chuman and Hiroaki Hiraga and Toru Hiruma and Noriaki Kameda and Chihiro Kanehira and Mitsunori Kaya and Rikuo Machinami and Akihiko Matsumine and Seiichi Matsumoto and Hideo Morioka and Yoshihiro Nishida and Kazuhisa Takahashi and Masazumi Tsuneyoshi and Takehiko Yamaguchi and Tsukasa Yonemoto",
year = "2018",
month = "9",
day = "1",
doi = "10.1002/cam4.1679",
language = "English",
volume = "7",
pages = "4308--4314",
journal = "Cancer Medicine",
issn = "2045-7634",
publisher = "John Wiley and Sons Ltd",
number = "9",

}

TY - JOUR

T1 - Carbon ion radiotherapy for unresectable localized axial soft tissue sarcoma

AU - and the Working Group for Carbon Ion Radiotherapy for Bone and Soft Tissue Sarcomas

AU - Imai, Reiko

AU - Kamada, Tadashi

AU - Araki, Nobuhito

AU - Abe, Satoshi

AU - Iwamoto, Yukihide

AU - Ozaki, Toshihumi

AU - Chuman, Hirokazu

AU - Hiraga, Hiroaki

AU - Hiruma, Toru

AU - Kameda, Noriaki

AU - Kanehira, Chihiro

AU - Kaya, Mitsunori

AU - Machinami, Rikuo

AU - Matsumine, Akihiko

AU - Matsumoto, Seiichi

AU - Morioka, Hideo

AU - Nishida, Yoshihiro

AU - Takahashi, Kazuhisa

AU - Tsuneyoshi, Masazumi

AU - Yamaguchi, Takehiko

AU - Yonemoto, Tsukasa

PY - 2018/9/1

Y1 - 2018/9/1

N2 - Carbon ion radiotherapy is known for its high-precision dose distribution and high biological effectiveness. We evaluated the results of carbon ion radiotherapy in 128 patients with unresectable localized axial soft tissue sarcoma at a single institution. The patients’ median age was 54 years, and the median follow-up period was 49.4 (range 6.4-146.4) months. The median tumor volume was 356 cm3. The 5-year local control, overall survival, and disease-free survival rates were 65%, 46%, and 39%, respectively. In the univariate analysis, tumor volume, local control, and incidences of metastases were significantly related to overall survival. In the multivariate analysis, tumor volume and local control were significantly related to overall survival. We did not find any factors related to local control. Five patients required surgical intervention because of adverse events in the bones. Carbon ion radiotherapy may be a treatment option for unresectable axial soft tissue sarcoma.

AB - Carbon ion radiotherapy is known for its high-precision dose distribution and high biological effectiveness. We evaluated the results of carbon ion radiotherapy in 128 patients with unresectable localized axial soft tissue sarcoma at a single institution. The patients’ median age was 54 years, and the median follow-up period was 49.4 (range 6.4-146.4) months. The median tumor volume was 356 cm3. The 5-year local control, overall survival, and disease-free survival rates were 65%, 46%, and 39%, respectively. In the univariate analysis, tumor volume, local control, and incidences of metastases were significantly related to overall survival. In the multivariate analysis, tumor volume and local control were significantly related to overall survival. We did not find any factors related to local control. Five patients required surgical intervention because of adverse events in the bones. Carbon ion radiotherapy may be a treatment option for unresectable axial soft tissue sarcoma.

KW - carbon ion radiotherapy

KW - charged particle therapy

KW - radiotherapy

KW - soft tissue sarcoma

UR - http://www.scopus.com/inward/record.url?scp=85050369837&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85050369837&partnerID=8YFLogxK

U2 - 10.1002/cam4.1679

DO - 10.1002/cam4.1679

M3 - Article

C2 - 30030906

AN - SCOPUS:85050369837

VL - 7

SP - 4308

EP - 4314

JO - Cancer Medicine

JF - Cancer Medicine

SN - 2045-7634

IS - 9

ER -